ANI Pharmaceuticals (Nasdaq:ANIP) - Aktienkurs, Nachrichten und Analyse

ANIP Aktienübersicht

ANIP grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	3/6
Vergangene Leistung	2/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

66.8% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 31.18% pro Jahr

In diesem Jahr profitabel geworden

Analysten sind sich einig, dass der Aktienkurs um 34.3%

Risikoanalyse

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Die Aktionäre wurden im vergangenen Jahr verwässert

Signifikante Insiderverkäufe in den letzten 3 Monaten

ANI Pharmaceuticals, Inc. Wettbewerber

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.1b

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$1.9b

Pacira BioSciences

NasdaqGS:PCRX

US$1.0b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$1.9b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für ANI Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	US$56.43
52-Wochen-Hoch	US$70.81
52-Wochen-Tief	US$48.20
Beta	0.76
11 Monat Veränderung	-8.00%
3 Monate Veränderung	-17.08%
1 Jahr Veränderung	-6.91%
33 Jahre Veränderung	86.48%
5 Jahre Veränderung	-15.89%
Veränderung seit IPO	795.71%

Aktuelle Nachrichten und Updates

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Aug 08

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Recent updates

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Aug 08

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Aktionärsrenditen

	ANIP	US Pharmaceuticals	US Markt
7D	-11.6%	-2.4%	-5.7%
1Y	-6.9%	8.4%	14.1%

Rendite im Vergleich zur Industrie: ANIP unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 9.3% erzielte.

Rendite vs. Markt: ANIP hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 14.1 erzielte.

Preisvolatilität

Is ANIP's price volatile compared to industry and market?
ANIP volatility
ANIP Average Weekly Movement	6.1%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.6%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: ANIP hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: ANIPDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2001	642	Nikhil Lalwani	www.anipharmaceuticals.com

ANI Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen, das verschreibungspflichtige Markenarzneimittel und Generika in den Vereinigten Staaten und Kanada entwickelt, herstellt und vertreibt. Das Unternehmen stellt orale Produkte in fester Dosierung, halbfeste, flüssige und topische Produkte, kontrollierte Substanzen und potente Produkte her und übernimmt die Auftragsentwicklung und -herstellung von pharmazeutischen Produkten. Es vertreibt seine Produkte über Einzelhandelsapothekenketten, Großhändler, Distributoren und Versandapotheken, Einkaufsgemeinschaften, Spezialapotheken und Krankenhäuser.

ANI Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von ANI Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
ANIP grundlegende Statistiken
Marktanteil	US$1.11b
Gewinn(TTM)	US$22.93m
Umsatz(TTM)	US$538.95m

48.0x

Kurs-Gewinn-Verhältnis

2.0x

Kurs-Umsatz-Verhältnis

Ist ANIP zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ANIP Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$538.95m
Kosten der Einnahmen	US$208.38m
Bruttogewinn	US$330.58m
Sonstige Ausgaben	US$307.65m
Umsatz	US$22.93m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	1.17
Bruttomarge	61.34%
Nettogewinnspanne	4.25%
Schulden/Eigenkapital-Verhältnis	59.4%

Wie hat sich ANIP auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ANIP Aktienübersicht

Belohnungen

Risikoanalyse

ANI Pharmaceuticals, Inc. Wettbewerber

NasdaqGS:COLL

US$1.1b

NasdaqGM:HRMY

US$1.9b

NasdaqGS:PCRX

US$1.0b

NasdaqGS:AMPH

US$1.9b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

Recent updates

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Erträge & Einnahmen